Press Releases

Proscia® has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Concentriq® AP-Dx. The clearance includes compatibility with the Leica Aperio® GT 450 DX slide scanner, cloud deployment, and a Predetermined Change Control Plan (PCCP). Concentriq AP-Dx is a digital pathology platform for primary diagnosis used by laboratories of all sizes. 

Built on a new AI-native architecture, Concentriq delivers clinically and scientifically grounded intelligence to decisions throughout drug discovery, development, and case review.

By adopting the Concentriq® platform, NextGen Pathology will lay an AI foundation for advancing its subspecialty services and positioning itself as a strategic partner for biopharmaceutical research.

Following Proscia’s Global Best in KLAS win in Europe, Concentriq is now the highest-rated digital pathology platform across multiple regions

Specialized CRO has delivered 750 neuroscience studies advancing drug R&D with digital pathology

100% of customers interviewed would buy again, citing trust for primary diagnosis at scale and a partnership they can count on

AWS HealthImaging integration delivers standards-based digital pathology at enterprise scale with DICOM and Proscia’s cloud-native platform

Proscia® is on track for 32,000 patients to be diagnosed on its Concentriq® software platform each day—a 400% increase year-over-year.

Funding led by global software investor Insight Partners comes as the surge in cancer cases compounds the impact of the shrinking pathologist workforce. The company will use the funds to grow its customer footprint and advance Concentriq, with focus on extending the platform’s core AI capabilities.

Proscia®, a leading provider of digital and computational pathology solutions, has received 510(k) clearance from the United States (U.S.) Food and Drug Administration (FDA) for its Concentriq® AP-Dx*. The digital pathology solution was cleared for the purpose of primary diagnosis.